Azathioprine (AZA)
Sponsors
Merck Sharp & Dohme LLC, Genzyme, a Sanofi Company, Hoffmann-La Roche, Sheikh Zayed Medical College, University of Pennsylvania
Conditions
Alopecia AreataAlopecia Areata(AA)Chrohn's DiseaseGenetic PolymorphismMucopolysaccharidosis INeuromyelitis Optica Spectrum DisorderRelapsing PolychondritisUlcerative Colitis
Phase 1
Phase 2
To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata
CompletedNCT06786689
Start: 2023-03-01End: 2023-09-30Updated: 2025-01-22
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
RecruitingNCT06941376
Start: 2025-08-01End: 2027-12-01Target: 20Updated: 2026-02-04
Phase 3
Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)
TerminatedNCT00537316
Start: 2007-07-31End: 2010-02-28Updated: 2017-04-12
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
CompletedNCT04660539
Start: 2021-03-02End: 2024-05-28Updated: 2024-12-27
Phase 4
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
RecruitingNCT07235904
Start: 2025-12-05End: 2028-10-31Target: 300Updated: 2025-12-16
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease
Not yet recruitingNCT07659353
Start: 2026-08-01End: 2029-03-31Target: 320Updated: 2026-06-22